CU23578A1 - Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal - Google Patents

Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal

Info

Publication number
CU23578A1
CU23578A1 CU20050168A CU20050168A CU23578A1 CU 23578 A1 CU23578 A1 CU 23578A1 CU 20050168 A CU20050168 A CU 20050168A CU 20050168 A CU20050168 A CU 20050168A CU 23578 A1 CU23578 A1 CU 23578A1
Authority
CU
Cuba
Prior art keywords
capsid protein
denges
vaccine composition
virus capsid
protection response
Prior art date
Application number
CU20050168A
Other languages
English (en)
Inventor
Ramundo Susana Vazquez
Morales Aida Zulueta
Vazquez Beatriz De La Caridad Sierra
Abarrategui Carlos Lopez
Vazquez Laura Lazo
Cruz Lisset Hermida
Prado Iris Valdes
Tirado Maria Guadalupe Guzman
Nieto Gerardo Enrique Guillen
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20050168A priority Critical patent/CU23578A1/es
Priority to ARP060104044A priority patent/AR058049A1/es
Priority to BRPI0616224A priority patent/BRPI0616224B8/pt
Priority to DK06791279.0T priority patent/DK1944038T3/en
Priority to PT67912790T priority patent/PT1944038E/pt
Priority to JP2008530308A priority patent/JP5657204B2/ja
Priority to ES06791279.0T priority patent/ES2444691T3/es
Priority to KR1020087008971A priority patent/KR101350318B1/ko
Priority to EP06791279.0A priority patent/EP1944038B1/en
Priority to CN2006800422806A priority patent/CN101304760B/zh
Priority to CA2622827A priority patent/CA2622827C/en
Priority to PCT/CU2006/000008 priority patent/WO2007031034A1/es
Priority to KR1020137022261A priority patent/KR20130100026A/ko
Priority to AU2006291863A priority patent/AU2006291863B2/en
Priority to RU2008114841/15A priority patent/RU2008114841A/ru
Priority to US12/067,129 priority patent/US7790173B2/en
Priority to MYPI2011003797A priority patent/MY161452A/en
Priority to MYPI20080715A priority patent/MY149395A/en
Priority to ZA200802740A priority patent/ZA200802740B/xx
Publication of CU23578A1 publication Critical patent/CU23578A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En esta invención se describe la obtención de la proteína de la cápsida de los serotipos del virus Dengue por vía recombinante y particulada capaz de inducir en el receptor una respuesta inmune protectora frente al reto viral, sin inducir el fenómeno de inmunoamplificación dependiente de Acs. También se describen compuestos vacunales que contienen las mezclas de las proteínas recombinantes de la cápsida con el dominio III de los cuatro serotipos del virus dengue. Estas proteínas y sus mezclas son aplicables a la industria farmacéutica en la obtención de preparados vacunales contra el dengue.
CU20050168A 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal CU23578A1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
ARP060104044A AR058049A1 (es) 2005-09-16 2006-09-15 Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica
BRPI0616224A BRPI0616224B8 (pt) 2005-09-16 2006-09-18 composição farmacêutica
DK06791279.0T DK1944038T3 (en) 2005-09-16 2006-09-18 Dengue virus capsid protein that induces a protective response AND PHARMACEUTICAL COMPOSITION
PT67912790T PT1944038E (pt) 2005-09-16 2006-09-18 Proteína da cápside do vírus da dengue que induz uma resposta protectora, e composição farmacêutica
JP2008530308A JP5657204B2 (ja) 2005-09-16 2006-09-18 デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物
ES06791279.0T ES2444691T3 (es) 2005-09-16 2006-09-18 Proteína de la cápside del virus del Dengue que induce una respuesta protectora y su composición farmacéutica
KR1020087008971A KR101350318B1 (ko) 2005-09-16 2006-09-18 보호 반응을 유도하는 댕기열 바이러스 캡시드 단백질 및약학적 조성물
EP06791279.0A EP1944038B1 (en) 2005-09-16 2006-09-18 Dengue virus capsid protein which induces a protective response and pharmaceutical composition
CN2006800422806A CN101304760B (zh) 2005-09-16 2006-09-18 诱导保护性应答的登革病毒衣壳蛋白以及药物组合物
CA2622827A CA2622827C (en) 2005-09-16 2006-09-18 Pharmaceutical compound capable of inducing immune protective response against dengue virus having the capsid protein of the dengue virus
PCT/CU2006/000008 WO2007031034A1 (es) 2005-09-16 2006-09-18 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición farmacéutica
KR1020137022261A KR20130100026A (ko) 2005-09-16 2006-09-18 보호 반응을 유도하는 댕기열 바이러스 캡시드 단백질 및 약학적 조성물
AU2006291863A AU2006291863B2 (en) 2005-09-16 2006-09-18 Dengue virus capsid protein which induces a protective response and pharmaceutical composition
RU2008114841/15A RU2008114841A (ru) 2005-09-16 2006-09-18 Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса
US12/067,129 US7790173B2 (en) 2005-09-16 2006-09-18 Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus
MYPI2011003797A MY161452A (en) 2005-09-16 2006-09-19 Dengue virus capsid protein which induces a protective response and pharmaceutical composition
MYPI20080715A MY149395A (en) 2005-09-16 2006-09-19 Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
ZA200802740A ZA200802740B (en) 2005-09-16 2008-03-27 Dengue virus capsid protein which induces a protective response and pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal

Publications (1)

Publication Number Publication Date
CU23578A1 true CU23578A1 (es) 2010-09-30

Family

ID=40132555

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal

Country Status (17)

Country Link
US (1) US7790173B2 (es)
EP (1) EP1944038B1 (es)
JP (1) JP5657204B2 (es)
KR (2) KR20130100026A (es)
CN (1) CN101304760B (es)
AR (1) AR058049A1 (es)
AU (1) AU2006291863B2 (es)
BR (1) BRPI0616224B8 (es)
CA (1) CA2622827C (es)
CU (1) CU23578A1 (es)
DK (1) DK1944038T3 (es)
ES (1) ES2444691T3 (es)
MY (2) MY149395A (es)
PT (1) PT1944038E (es)
RU (1) RU2008114841A (es)
WO (1) WO2007031034A1 (es)
ZA (1) ZA200802740B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
WO2012178196A2 (en) * 2011-06-24 2012-12-27 La Jolla Institute For Allergy And Immunology Protection against dengue virus and prevention of severe dengue disease
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
MX2015004191A (es) * 2012-10-04 2016-04-04 Univ Leland Stanford Junior Metodos y reactivos para la deteccion, cuantificacion y serotipado de virus del dengue.
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018169550A1 (en) * 2017-03-17 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time rt-pcr assay for detection of dengue, chikungunya, and zika viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0872553B1 (en) 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
DE69624815T2 (de) * 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
AU2933797A (en) 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
EP1021544B1 (en) * 1997-10-08 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Chimeric vaccine against tick-borne encephalitis virus
ES2323845T3 (es) 1999-04-30 2009-07-27 Novartis Vaccines And Diagnostics, Inc. Secuencias genomicas de neisseria y procedimientos de uso.
CA2755964C (en) * 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003300831A1 (en) 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
MY149395A (en) 2013-08-30
CA2622827C (en) 2015-12-15
KR101350318B1 (ko) 2014-01-14
ES2444691T3 (es) 2014-02-26
CN101304760A (zh) 2008-11-12
EP1944038A1 (en) 2008-07-16
PT1944038E (pt) 2014-02-21
DK1944038T3 (en) 2014-03-03
CN101304760B (zh) 2013-03-13
KR20080048068A (ko) 2008-05-30
AU2006291863B2 (en) 2012-09-20
US20080311157A1 (en) 2008-12-18
ZA200802740B (en) 2008-12-31
RU2008114841A (ru) 2009-10-27
BRPI0616224B1 (pt) 2019-01-15
CA2622827A1 (en) 2007-03-22
MY161452A (en) 2017-04-14
JP2009507864A (ja) 2009-02-26
EP1944038B1 (en) 2013-11-27
BRPI0616224B8 (pt) 2021-05-25
AU2006291863A1 (en) 2007-03-22
JP5657204B2 (ja) 2015-01-21
KR20130100026A (ko) 2013-09-06
BRPI0616224A2 (pt) 2013-02-19
US7790173B2 (en) 2010-09-07
WO2007031034A1 (es) 2007-03-22
AR058049A1 (es) 2008-01-23

Similar Documents

Publication Publication Date Title
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
CY1124371T1 (el) Ιοσωματια aav me μειωμενη ανοσοαντιδραστικοτητα και χρησεις αυτων
CY1125387T1 (el) Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2011002453A1 (es) Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc.
DK1375670T3 (da) Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
AR061894A1 (es) Vacunas para malaria
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
MX389111B (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
EP4007810A4 (en) RECOMBINANT BACULOVIRUS WITH AFRICAN SWINE FEVER VIRUS PROTEINS, AND IMMUNOLOGICAL COMPOSITION COMPRISING THEM
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2007000529A1 (es) Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende.
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
MX2017014417A (es) Vacunas contra el dengue.
AR058049A1 (es) Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica
CL2007002370A1 (es) Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales.
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus
WO2018115509A3 (en) New flavivirus vaccine